Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
2 participants
INTERVENTIONAL
2019-10-28
2020-03-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of LY3405105 in Participants With Advanced Cancer
NCT03770494
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
NCT02784795
A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread
NCT01648764
LY293111 in Treating Patients With Advanced Solid Tumors
NCT00006375
A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
NCT03522142
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part A: 10 milligrams (mg) LY3435151
Participants received intravenous (IV) push or IV bolus infusion of 10 mg LY3435151.
LY3435151
Administered IV
Part B: LY3435151 + Pembrolizumab Dose Escalation
Pembrolizumab was not administered as study was terminated before completion of Part A of the dose escalation period.
LY3435151
Administered IV
Pembrolizumab
Administered IV
Part C: LY3435151 Dose Expansion
Participants were not enrolled in to this arm, as trial was terminated in dose escalation phase.
LY3435151
Administered IV
Part D: LY3435151 + Pembrolizumab Dose Expansion
Participants were not enrolled in to this arm, as trial was terminated in dose escalation phase.
LY3435151
Administered IV
Pembrolizumab
Administered IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LY3435151
Administered IV
Pembrolizumab
Administered IV
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant must have stopped other forms of treatment for cancer, which your study doctor will discuss with you
* Participant must be able and willing to provide a sample of your tumor before beginning treatment and once while on treatment. For certain tumor types, the outcome of the biopsy may exclude you from the study treatment (for Phase 1b)
* Participant must agree to use birth control
* Participant must have progressed through or are intolerant to therapies with known clinical benefit, which your study doctor will discuss with you
Exclusion Criteria
* Participant must not have an autoimmune disease, which your study doctor will discuss with you
* Participant must not use corticosteroids, which your study doctor will discuss with you
* Participant must not have heart disease, Crohn's disease or brain cancer
* Participant must not be pregnant or breastfeeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
National Cancer Center Hospital
Chuo-Ku, Tokyo, Japan
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
A Study of LY3435151 in Participants With Solid Tumors
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
J1Q-MC-JZIA
Identifier Type: OTHER
Identifier Source: secondary_id
17364
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.